This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Pharma Solutions operates 10 research and development and/or production sites globally
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Additional capacity broadens Grace’s fine chemical capabilities for API production
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
BHL will undertake the development and supply of these molecules
Subscribe To Our Newsletter & Stay Updated
